| |
Crude OR
|
95% CI
|
Adjusted OR
|
95% CI
|
|---|
|
Age
| | | | |
|
10 to 14
|
1*
|
0.74–0.89
|
1
| |
|
15 to 19
|
0.81
|
0.92
|
0.78–1.09
|
|
Gender
| | | | |
|
Male
|
1*
|
1.17–1.41
|
1*
| |
|
Female
|
1.29
|
1.21
|
1.05–1.39
|
|
Method into ART at facility
| | | | |
|
Transferred in from another facility
|
1
| | | |
|
New ART patient
|
0.94
|
0.85–1.04
| | |
|
Started IPT
| | | | |
|
No
|
1*
| |
1
| |
|
Yes
|
1.19
|
1.01–1.25
|
1.04
|
0.89–1.23
|
|
History of TB
| | | | |
|
No
|
1*
| |
1
| |
|
Yes
|
0.55
|
0.35–0.86
|
0.73
|
0.37–1.26
|
|
WHO stage
| | | | |
|
Stage 1
|
1*
| |
1
| |
|
Stage 2
|
0.83
|
0.73–0.94
|
0.88
|
0.75–1.04
|
|
Stage 3
|
0.77
|
0.67–0.91
|
0.86
|
0.72–1.03
|
|
Stage 4
|
0.76
|
0.57–1.00
|
0.85
|
0.57–1.26
|
|
ART initiation on same day
| | | | |
|
No
|
1
| | | |
|
Yes
|
1.21
|
0.93–1.57
| | |
|
Duration on ART
| | | | |
|
6 to 11 months
|
1*
| |
1*
| |
|
12 to 17 months
|
0.73
|
0.54–0.99
|
0.62
|
0.25–1.55
|
|
18 to 24 months
|
1.04
|
0.75–1.43
|
0.37
|
0.15–0.93
|
|
25 months +
|
0.73
|
0.58- 0.92
|
0.60
|
0.22–1.28
|
|
Age at art start
| | | | |
|
0 to 9 years
|
1*
| |
1
| |
|
10 to 14 years
|
0.79
|
0.72–0.87
|
0.88
|
0.74–1.04
|
|
15 to 19 years
|
1.44
|
1.24–1.67
|
1.30
|
0.97–1.75
|
|
Pregnant during ART start
| | | | |
|
No
|
1*
| | | |
|
Yes
|
1.53
|
1.18–1.98
| | | |
|
CD4 count at last visit
| | | | |
|
CD4 < 200
|
1*
| |
1*
| | |
|
CD4 > 200
|
2.45
|
2.14–2.79
|
2.53
|
2.06–3.11
|
|
CD4 count at baseline
| | | | | |
|
CD4 < 200
|
1*
| |
1*
| | |
|
CD4 > 200
|
1.19
|
1.05–1.36
|
0.73
|
0.61–0.87
|
|
Second line
| | | | |
|
No
|
1*
| |
1*
| | |
|
Yes
|
0.38
|
0.34–0.43
|
0.41
|
0.34–0.49
|
- *p-value statistically significant at 5%
